Term
|
Definition
Inhibit P2Y12 ADP platelet receptor activation |
|
|
Term
|
Definition
Inhibit P2Y12 ADP platelet receptor activation |
|
|
Term
|
Definition
Inhibit platelet activator TxA2 synthesis and secretion |
|
|
Term
|
Definition
Inhibit platelet activator TxA2 synthesis and secretion |
|
|
Term
|
Definition
increase platelet cAMP levels by acting on PLA2 |
|
|
Term
|
Definition
Inhibit GP IIbIIIa receptors |
|
|
Term
|
Definition
Inhibit GP IIbIIIa receptors |
|
|
Term
|
Definition
Inhibit GP IIbIIIa receptors |
|
|
Term
|
Definition
TPO agonist; is a nonpeptide mimetic; given oral |
|
|
Term
|
Definition
TPO agonist; is a peptide mimetic; given subcutaneous |
|
|
Term
|
Definition
inhibits Vitamin K Epoxide Reductase = VKOR |
|
|
Term
|
Definition
positively charged molecule that helps remove free heparin |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
pentasaccharide binds to antithrombin |
|
|
Term
|
Definition
Not used analog of fondaparinux - a pentasaccharide that binds to antithrombin |
|
|
Term
|
Definition
biotinlated idraparinux (which is a pentasaccharide that binds to antithrombin) |
|
|
Term
|
Definition
Direct thrombin inhibitor |
|
|
Term
|
Definition
direct thrombin inhibitor with smaller connecting chain than hirudin |
|
|
Term
|
Definition
Direct thromin inhibitor, binds only to catalytic site |
|
|
Term
|
Definition
oral direct thrombin inhibitor that only binds to catalytic site |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
antibody against C5, preventing terminal compliment activation |
|
|
Term
|
Definition
first line Fe chelator, subcu injection |
|
|
Term
|
Definition
orally active chelating agent, but not in US b/c of potential safety problems |
|
|
Term
|
Definition
|
|
Term
|
Definition
increase amount of HbF for sickle cell disease |
|
|
Term
|
Definition
|
|
Term
|
Definition
structral analog of thalidomide, anti angiogenic and immunomodulatory |
|
|
Term
|
Definition
|
|
Term
|
Definition
anti-CD52 (lymphocyte marker) |
|
|
Term
|
Definition
alkylating agent, main toxicity is hemorrhagic cystitis |
|
|
Term
|
Definition
alkylating agent; main toxicity is CNS effects |
|
|
Term
|
Definition
platinum; toxicities = nephrotoxicity, nausea/vomitting, neurotoxicity, ototoxicity |
|
|
Term
|
Definition
platnium; toxicity = myelosuppression |
|
|
Term
|
Definition
platinum; toxicity = neurotoxicity, cold intolerance |
|
|
Term
|
Definition
anthracycline; toxicity = cardiac, myelosuppression, nausea/vomitting |
|
|
Term
|
Definition
antibiotic; toxicity = pulmonary, NOT bone marrow, oral mucositis |
|
|
Term
Etoposide (epipodophyllotoxins) |
|
Definition
Topoisomerase II inhibitor (stabilizes double stranded breaks |
|
|
Term
Irinotecan (camptothecins) |
|
Definition
Topoisomerase I inhibitor - stabilizes single strand breaks |
|
|
Term
|
Definition
folate analog; inhibits dihydrofolate reductase |
|
|
Term
|
Definition
Folate supplement used to prevent toxicity from methotrexate |
|
|
Term
|
Definition
antimetabolite; inhibits thymidylate synthetase, which converts dUMP to dTMP |
|
|
Term
|
Definition
|
|
Term
|
Definition
cytosine analog anti-metabolite |
|
|
Term
|
Definition
adenosine analog anti-metabolite |
|
|
Term
|
Definition
adenosine analog anti-metabolite |
|
|
Term
|
Definition
adenosine analog anti-metabolite |
|
|
Term
|
Definition
guanine analog anti-metabolite |
|
|
Term
|
Definition
bind to tubulin to stabilize the spindle |
|
|
Term
|
Definition
vinca alkaloid; toxicity = neuropathy |
|
|
Term
|
Definition
vinca alkaloid; toxicity = myelosuppression |
|
|
Term
|
Definition
radioimmunotherapy that is anti-CD |
|
|
Term
|
Definition
|
|
Term
|
Definition
all trans retinoic acid for APL |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
inhibitor of protein elongation (CML) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
synthetic androgen w/ anabolic properties |
|
|
Term
|
Definition
androgen recptor antagonist |
|
|
Term
|
Definition
androgen receptor antagonists |
|
|
Term
|
Definition
5alpha reductase inhibitor |
|
|
Term
|
Definition
5alpha reductase inhibitor |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
estrogen causing vaginal cancer |
|
|
Term
|
Definition
androgens that bind to progestin receptors |
|
|
Term
|
Definition
|
|
Term
|
Definition
oral synthetic progestin receptor agonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
SERM blocking feedback of estrogen |
|
|
Term
|
Definition
progestin antagonist; glucocorticoid receptor antagonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
integrate into bone, inhibit osteoclasts |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
inhibit thyroid peroxidase |
|
|
Term
|
Definition
inhibits thyroid peroxidase, inhibits T4-->T3 |
|
|
Term
|
Definition
beta adrenergic receptor blocker |
|
|
Term
|
Definition
inhibit thyroid hormone release; antagonize TSH, inhibit thyroid peroxidase |
|
|
Term
|
Definition
|
|
Term
|
Definition
inhibit steroid synthesis |
|
|
Term
|
Definition
insulin given with protamine, medium duration |
|
|
Term
|
Definition
modifications of insulin to prevent dimerization --> quick acting |
|
|
Term
|
Definition
modification in insulin --> less dimerization --> fast acting |
|
|
Term
|
Definition
form microprecipitates of insulin, so longer acting |
|
|
Term
|
Definition
form precipitates of insulin, so longer lasting |
|
|
Term
|
Definition
closes Katp channels, leading to insulin release |
|
|
Term
|
Definition
closes Katp channels, leading to insulin release |
|
|
Term
|
Definition
increases glucose-dependent release of insulin, increased weight loss / satiety |
|
|
Term
dipeptidylpeptidase inhibitors |
|
Definition
inhibits enzyme that breaks down GLP-1 |
|
|
Term
|
Definition
increases insulin sensitivity in muscle and adipose by binding to PPARgamma |
|
|
Term
alpha-glucosidase inhibitor |
|
Definition
prevents breakdown of sugars, so prevents absorption |
|
|
Term
|
Definition
affects satiety, post prandial glucose concentrations |
|
|
Term
|
Definition
decrease glucose production by liver, increase utilization |
|
|